Aileron Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aileron Therapeutics generated cash of -$19,808,000, which is more than the previous year. Cash used in financing activities reached the amount of $15,794,000 last year. Net change in cash is therefore $12,119,000.
Cash Flow
| 2015 | -11.71M | 10.62M | -1.35M |
|---|---|---|---|
| 2016 | -15.01M | -25K | 31.98M |
| 2017 | -20.53M | -38.91M | 50.59M |
| 2018 | -27.92M | 24.68M | 2.51M |
| 2019 | -26.47M | -2.81M | 23.96M |
| 2020 | -20.47M | 6.41M | 15.8M |
| 2021 | -23.75M | -35.91M | 55.65M |
| 2022 | -24.86M | 26.45M | 0 |
| 2023 | -19.80M | 16.19M | 15.79M |
ALRN Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 5.21M | 3.62M | 7.63M | 5.90M | 11.22M | 11.95M | 20.71M | 3.76M | 6.20M |
Operating activities | |||||||||
Net income | -15.73M | -27.32M | -26.16M | -21.15M | -29.36M | -31.54M | -22.60M | -18.12M | -12.87M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 119K | 169K | 121K | 163K | 155K | 218K | 129K | 232K | 325K |
Stock-based compensation expense | 1.19M | 2.08M | 2.26M | 1.89M | 2.11M | 0 | 1.74M | 688K | 626K |
| Deferred income tax benefit | 1.19M | 2.08M | 2.26M | 1.89M | 2.11M | 0 | 1.74M | 688K | 626K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -4.98M | 510K | -386K | 116K | -277K | 130K | -241K | 1.21M | -237K |
Cash generated by operating activities | -19.80M | -24.86M | -23.75M | -20.47M | -26.47M | -27.92M | -20.53M | -15.01M | -11.71M |
Investing activities | |||||||||
Purchases Of Investments | 0 | -21.85M | -73.57M | -10.03M | -27.23M | -31.19M | -71.05M | -12.63M | -2.36M |
Investments In Property Plant And Equipment | 0 | 0 | -157K | -5K | -151K | -4.42M | -142K | 0 | -94K |
Acquisitions Net | -96K | 0 | 66K | 208K | 2.66K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 16.19M | 26.45M | -35.91M | 6.41M | -2.81M | 24.68M | -38.91M | -25K | 10.62M |
Financing activities | |||||||||
Common Stock Issued | 0 | 0 | 55.65M | 15.41M | 23.79M | 0 | 52.31M | 0 | -1.35M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -91K |
Repayments of term debt | 0 | 0 | 0 | -387K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 15.79M | 0 | 55.65M | 15.8M | 23.96M | 2.51M | 50.59M | 31.98M | -1.35M |
Net Change In Cash | 12.11M | 1.59M | -4.01M | 1.73M | -5.32M | -723K | -8.85M | 16.94M | -2.44M |
Cash at end of period | 17.33M | 5.21M | 3.62M | 7.63M | 5.90M | 11.22M | 11.86M | 20.71M | 3.76M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |